知Yizhi Daily
← Back to this edition

World

FDA Requires GLP-1 Drugs to Add Warning for Rare Eye Condition

Edition 2026-11-11 · 08:00 Beijing time

The U.S. Food and Drug Administration is requiring manufacturers of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound to add a warning about NAION. The condition can cause sudden, painless vision loss in one eye and even permanent blindness, but ophthalmology organizations say any added risk appears small and patients should not stop taking the drugs on their own.

According to the BBC, the U.S. Food and Drug Administration is requiring manufacturers of popular weight-loss and blood-sugar-lowering GLP-1 drugs to add a label warning about non-arteritic anterior ischemic optic neuropathy. Ozempic, Wegovy, Mounjaro, and Zepbound are all covered by the requirement. The condition occurs when blood vessels supplying the optic nerve become blocked and the nerve is deprived of oxygen, potentially causing painless vision loss in one eye; in severe cases, the visual damage can be permanent.

The FDA said it carefully reviewed reports of NAION among GLP-1 users and other studies, and concluded that people taking these drugs have an increased risk of rare NAION events. The regulator also said some studies were difficult to assess because people with obesity and type 2 diabetes may themselves have NAION risk factors unrelated to the drugs, and the reason for the elevated risk among users is currently unclear.

The American Academy of Ophthalmology said in a statement that any added risk appears small and that it has not been established that these drugs cause NAION. The academy noted that GLP-1 drugs provide important benefits for patients with diabetes, obesity, and heart disease, and patients should not stop taking them without consulting a doctor; if they experience sudden, painless vision loss in one eye, they should see an ophthalmologist as soon as possible. There is currently no known treatment that can reverse vision loss caused by NAION.

Novo Nordisk, the maker of Wegovy, said existing data do not establish a causal relationship and that the company will continue to monitor drug safety. European Union drug regulators previously said NAION may affect as many as 1 in 10,000 semaglutide users; a U.S. study published two years ago analyzing 17000 patients found that users were four times as likely to be diagnosed with NAION as non-users, but the researchers involved said the findings were important but still preliminary and required more research.

Original sources

BBC World ↗
Back to this editionOpen interactive reader